Reply to F.D. Leonard.

Autor: Bustoros M; Mark Bustoros, MD; Romanos Sklavenitis-Pistofidis, MD; Jorge J. Castillo, MD; Steven P. Treon, MD, PhD; and Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA., Sklavenitis-Pistofidis R; Mark Bustoros, MD; Romanos Sklavenitis-Pistofidis, MD; Jorge J. Castillo, MD; Steven P. Treon, MD, PhD; and Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA., Castillo JJ; Mark Bustoros, MD; Romanos Sklavenitis-Pistofidis, MD; Jorge J. Castillo, MD; Steven P. Treon, MD, PhD; and Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA., Treon SP; Mark Bustoros, MD; Romanos Sklavenitis-Pistofidis, MD; Jorge J. Castillo, MD; Steven P. Treon, MD, PhD; and Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA., Ghobrial IM; Mark Bustoros, MD; Romanos Sklavenitis-Pistofidis, MD; Jorge J. Castillo, MD; Steven P. Treon, MD, PhD; and Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA.
Jazyk: angličtina
Zdroj: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Oct 10; Vol. 37 (29), pp. 2701-2702. Date of Electronic Publication: 2019 Aug 19.
DOI: 10.1200/JCO.19.01708
Databáze: MEDLINE